These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 18566535)

  • 1. Mutant molecules of interest in myeloproliferative neoplasms: introduction.
    Tefferi A
    Acta Haematol; 2008; 119(4):192-3. PubMed ID: 18566535
    [No Abstract]   [Full Text] [Related]  

  • 2. New molecular insights in myelodysplastic and myeloproliferative disorders.
    Emanuel PD
    Clin Adv Hematol Oncol; 2005 Jun; 3(6):459-60. PubMed ID: 16167021
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinicopathological features of unbalanced translocation Der(1;7)(q10;p10) in myeloid neoplasms.
    So CC; Ma ES; Wan TS; Yip SF; Chan LC
    Leuk Res; 2008 Jun; 32(6):1000-1. PubMed ID: 17980911
    [No Abstract]   [Full Text] [Related]  

  • 4. NPM1 mutations may reveal acute myeloid leukemia in cases otherwise morphologically diagnosed as myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms.
    Forghieri F; Paolini A; Morselli M; Bigliardi S; Bonacorsi G; Leonardi G; Coluccio V; Maccaferri M; Fantuzzi V; Faglioni L; Colaci E; Soci F; Nasillo V; Messerotti A; Arletti L; Pioli V; Zucchini P; Quadrelli C; Corradini G; Giacobbi F; Vallerini D; Riva G; Barozzi P; Lagreca I; Marasca R; Narni F; Mecucci C; Ottaviani E; Martinelli G; Falini B; Luppi M; Potenza L
    Leuk Lymphoma; 2015; 56(11):3222-6. PubMed ID: 25813079
    [No Abstract]   [Full Text] [Related]  

  • 5. Molecular pathways in myelodysplastic syndromes and acute myeloid leukemia: relationships and distinctions-a review.
    Bernasconi P
    Br J Haematol; 2008 Sep; 142(5):695-708. PubMed ID: 18540941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Focus on myeloproliferative diseases and myelodysplastic syndromes.
    Van Etten RA; Shannon KM
    Cancer Cell; 2004 Dec; 6(6):547-52. PubMed ID: 15607959
    [No Abstract]   [Full Text] [Related]  

  • 7. Targeting of the Hedgehog pathway in myeloid malignancies: still a worthy chase?
    Khan AA; Harrison CN; McLornan DP
    Br J Haematol; 2015 Aug; 170(3):323-35. PubMed ID: 25892100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The World Health Organization (WHO) classification of the myeloid neoplasms.
    Vardiman JW; Harris NL; Brunning RD
    Blood; 2002 Oct; 100(7):2292-302. PubMed ID: 12239137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The new WHO nomenclature: introduction and myeloid neoplasms.
    Rodak BF; Leclair SJ
    Clin Lab Sci; 2002; 15(1):44-54. PubMed ID: 12778956
    [No Abstract]   [Full Text] [Related]  

  • 10. Myelodysplastic syndromes (MDSs) and acute myelogenous leukemia (AML) comprise a closely linked continuum of malignant hematologic diseases. Introduction.
    Baylin SB; Mufti GJ
    Nat Clin Pract Oncol; 2005 Dec; 2 Suppl 1():S1-3. PubMed ID: 16341235
    [No Abstract]   [Full Text] [Related]  

  • 11. The myelodysplastic syndromes and myeloproliferative disorders.
    Williams JL
    Clin Lab Sci; 2004; 17(4):223-34. PubMed ID: 15559729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic myeloproliferative disorders--introduction.
    Skoda R; Prchal JT
    Semin Hematol; 2005 Oct; 42(4):181-3. PubMed ID: 16210031
    [No Abstract]   [Full Text] [Related]  

  • 13. Aberrant histone modifications induced by mutant ASXL1 in myeloid neoplasms.
    Asada S; Kitamura T
    Int J Hematol; 2019 Aug; 110(2):179-186. PubMed ID: 30515738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of ras gene mutations in myeloproliferative disorders.
    Liu ET
    Clin Lab Med; 1990 Dec; 10(4):797-807. PubMed ID: 2272174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Farnesyltransferase inhibitors and their potential role in therapy for myelodysplastic syndromes and acute myeloid leukaemia.
    Braun T; Fenaux P
    Br J Haematol; 2008 May; 141(5):576-86. PubMed ID: 18410457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNMT3A mutations in myeloproliferative neoplasms.
    Stegelmann F; Bullinger L; Schlenk RF; Paschka P; Griesshammer M; Blersch C; Kuhn S; Schauer S; Döhner H; Döhner K
    Leukemia; 2011 Jul; 25(7):1217-9. PubMed ID: 21537334
    [No Abstract]   [Full Text] [Related]  

  • 17. Mutational analysis of BCORL1 in the leukemic transformation of chronic myeloproliferative neoplasms.
    Rotunno G; Guglielmelli P; Biamonte F; Rumi E; Cazzola M; Vannucchi AM
    Ann Hematol; 2014 Mar; 93(3):523-4. PubMed ID: 23793880
    [No Abstract]   [Full Text] [Related]  

  • 18. Special Issue "Advances in Molecular Pathogenesis and Targeted Therapies for Myeloid Neoplasms".
    Kok CH; Yeung DT; Hiwase DK
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone marrow cells of myelodysplastic syndromes exhibit significant expression of apollon, livin and ILP-2 with reduction after transformation to overt leukemia.
    Abe S; Yamamoto K; Hasegawa M; Inoue M; Kurata M; Hirokawa K; Kitagawa M; Nakagawa Y; Suzuki K
    Leuk Res; 2005 Sep; 29(9):1095-6. PubMed ID: 16038738
    [No Abstract]   [Full Text] [Related]  

  • 20. Analysis of serum Sialyl-Lewis(x) antigen levels in acute leukemias, myelodysplastic syndromes, myeloproliferative disorders and malignant lymphomas.
    Takubo T; Shibata H; Terada Y; Aoyama Y; Nakamae H; Yamamura R; Shima E; Makita K; Tanaka K; Ohta K; Yamane T; Hino M; Hashimoto S; Kamitani T; Tatsumi N
    Leuk Lymphoma; 2002 Sep; 43(9):1889-91. PubMed ID: 12685851
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.